Arecor and GSK Form Collaboration to Advance New Vaccines

Arecor and GSK Form Collaboration to Advance New Vaccines

Arecor and GSK have entered into a license agreement to develop advanced formulations of vaccines combining Arecor's unique formulation technologies with GSK's proprietary vaccines.  GSK and Arecor have collaborated to develop new approaches which could offer significant improvements to the administration of several vaccines in development.  In return for the license to their technology, Arecor will receive payments on relevant development milestones and royalties on sales.

Tom Saylor, CEO of Arecor, stated, "Arecor is pleased to work closely with one of the global leaders in vaccine products and technology.  The relationship with GSK offers Arecor the potential to apply its broad-ranging expertise in biomolecule stabilisation to specific projects with GSK."

Arecor Limited was established to provide formulation solutions to pharmaceutical and biotech companies developing proteins, vaccines and diagnostics based upon new insights into stabilization of biologics.  Proteins and vaccines are often fragile entities, and stability can represent significant constraints in the development of new products and extending the use of existing products.  Arecor has developed ArestatTM, a patented set of tools for stabilization which address the main pathways of degradation.  As a simple reformulation, ArestatTM can be readily incorporated into standard manufacturing practice, without covalent modification of the biologic and using excipients approved for the route of delivery. Arecor currently has active feasibility programs and licenses with many of the top pharmaceutical and biotech companies on a wide range of proteins and vaccines

Suggested Articles

Seven years after regaining the fibrosis drug it had licensed out to Stromedix, Biogen is pulling the plug on a phase 2 study.

Smaller biotechs are continuing their biopharma hiring spree as two startups nab some big names for their aspiring cancer drug research.

In a 7-2 vote, an FDA panel backed Aimmune’s peanut allergy treatment for approval. It desensitizes patients with increasing doses of peanut protein.